Skip to Content

Opioids without Addiction

Nektar Therapeutics is developing a painkiller that may enter the brain too slowly to be abused.
September 2, 2013

A new kind of opioid could offer patients pain relief with less risk of addiction and sedation.

In human tests, painkiller abusers found the investigational opioid “boring,” says Nektar Therapeutics’ chief medical officer, Rob Medve. “There is no joy or euphoria associated with the drug,” he says. And yet human trials show that the compound increases pain tolerance.

Opioids, which include morphine, remain the top choice for treating severe pain because they offer potent relief, but they also boost dopamine pathways in the brain, which causes an intensely rewarding high that can trigger repeated, chronic use and eventually addiction. According to the U.S. Department of Health and Human Services, nearly two million American abuse or are addicted to opioids, and nearly 14,000 overdose on these drugs in a year.

Researchers have been working for decades to develop more benign forms of these effective painkillers. “People have been trying to separate the beneficial analgesic effects of opioids from the side effects,” says Jane Aldrich, a medicinal chemist studying opioids at the University of Kansas. “It’s been a challenge, and one that we haven’t solved yet.”

Nektar’s approach is to add a side chain to a derivative of morphine, which changes the way the molecule behaves in the body. The addition slows the rate at which the compound enters the brain, in part by making it more difficult for it to cross the blood-brain barrier, the protective layers that surrounds blood vessels in the brain and regulates what can enter, says Steve Doberstein, chief scientific officer of Nektar. That reduces the risk of abuse, he says.

“Opioid drugs have a higher abuse liability the faster they get into the brain,” Doberstein says. Heroin, for example, is a form of morphine that moves very quickly into the brain, and that rush of the drug into the nervous system is associated with euphoria.

But the Nektar compound still provides pain control, says Medve. “We know you can get very good analgesia by having an opioid go in slowly to the brain and not produce the dopamine spike,” he says. “They are separable.” Other side effects, such as sedation and respiratory depression, may also be reduced, he says. The company has completed human safety trials and expects to have results from early efficacy tests in September.

Keep Reading

Most Popular

A Roomba recorded a woman on the toilet. How did screenshots end up on Facebook?

Robot vacuum companies say your images are safe, but a sprawling global supply chain for data from our devices creates risk.

A startup says it’s begun releasing particles into the atmosphere, in an effort to tweak the climate

Make Sunsets is already attempting to earn revenue for geoengineering, a move likely to provoke widespread criticism.

10 Breakthrough Technologies 2023

Every year, we pick the 10 technologies that matter the most right now. We look for advances that will have a big impact on our lives and break down why they matter.

These exclusive satellite images show that Saudi Arabia’s sci-fi megacity is well underway

Weirdly, any recent work on The Line doesn’t show up on Google Maps. But we got the images anyway.

Stay connected

Illustration by Rose Wong

Get the latest updates from
MIT Technology Review

Discover special offers, top stories, upcoming events, and more.

Thank you for submitting your email!

Explore more newsletters

It looks like something went wrong.

We’re having trouble saving your preferences. Try refreshing this page and updating them one more time. If you continue to get this message, reach out to us at customer-service@technologyreview.com with a list of newsletters you’d like to receive.